DigiNepal · drugs

Bendamustine

Bendamustine is used for: Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Common side effects include: The following clinically significant serious adverse reactions are discussed in greater detail in other sections of the prescribing information. Bendamustine. Used for (FDA label): Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. How it works: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. Do not use if: Bendamustine hydrochloride injection is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, absolute ethanol, sodium hydroxide and monothioglycerol. Common side effects: The following clinically significant serious adverse reactions are discussed in greater detail in other sections of the prescribing information. Pregnancy (label summary): There are no available data on bendamustine hydrochloride use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. General information only, not medical advice and not a prescription. No doses are given. Always consult a doctor or pharmacist before starting, stopping or changing any medicine, especially in pregnancy, breastfeeding, children, older age or with other medicines.

Source: FDA SPL label (openFDA/DailyMed); RxNorm (NLM)
Licence: FDA SPL label text via openFDA/DailyMed: public domain. RxNorm normalised names (RXNORM source): NLM, no licence required. AlifZetta text CC BY 4.0.
As of: 2026-11-07
Curated by AlifZetta SI (axz.si) and shown on DigiNepal with attribution.